<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394845</url>
  </required_header>
  <id_info>
    <org_study_id>GN42043</org_study_id>
    <nct_id>NCT04394845</nct_id>
  </id_info>
  <brief_title>A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants</brief_title>
  <official_title>Assessment of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Invicro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the biodistribution, safety and tolerability of a
      single dose of [18F]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Source Organ Counts Based on Individualized Organ Volumes of Interest (VOIs)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Source Organ Residence Time (Total Number of Disintegrations)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Radiation Absorbed Dose Estimates in Target Organs and Whole Body Based on Standard Medical Internal Radiation Dose (MIRD) Methodology</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to 5 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>[18F]GTP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>[18F]GTP1</intervention_name>
    <description>[18F]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]), with a maximum drug mass dose of 10 microgram (Î¼g).</description>
    <arm_group_label>[18F]GTP1</arm_group_label>
    <other_name>[18F]G02941054</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Healthy with no clinically relevant finding on physical examination at screening and
             prior to radiopharmaceutical administration

          -  Female participants must be willing to avoid pregnancy and refrain from donating eggs
             during the treatment period and for 30 days after the final dose

          -  Male participants with partners of childbearing potential must commit to the use of
             two methods of contraception for the study duration and 90 days after the last dose

          -  Male participants must not donate sperm for the duration of the study and 90 days
             after the last dose

          -  Participants must have both Japanese parents and all Japanese grandparents

        Key exclusion criteria:

          -  Participants with any significant medical disorder or disease expected to interfere
             with the study

          -  Current or prior history (within a six-month period) of exposure to nicotine products

          -  History of drug or alcohol abuse within 12 months prior to screening

          -  Prior participation in other research protocols or clinical care in the last year,
             such that radiation exposure combined with that from the present study exceeds an
             effective dose of 50 millisievert (mSv), the allowable annual limit for research
             participants as established by the US Federal Guidelines

          -  Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial
             dosing

          -  Use of over the counter (OTC) medication, dietary supplements, or vitamins, within 2
             weeks prior to initial dosing

          -  Known hypersensitivity to any component of the formulation of [18F]GTP1 or related
             compounds

          -  Major surgery, or donation or loss of 400 mL or more of blood within 4 weeks prior to
             initial dosing

          -  History of immunodeficiency diseases, including positive human immunodeficiency virus
             (HIV) test

          -  Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody

          -  Women who are pregnant, lactating or breastfeeding

          -  Unsuitable veins for repeated venipuncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN42043 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Invicro, a Konica Minolta company</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

